Review article · 2026 · Open access
In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation
Journal of Controlled Release, 400(Pt A), 115511 · Published 31 October 2026 · DOI 10.1016/j.jconrel.2026.115511
In brief
“In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation” is a 2026 review article by Yujie Ren and 2 co-authors, published in Journal of Controlled Release. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Controlled Release.
- Citations
- 0
- References
- 104
- Authors
- 3
Abstract
Conventional ex vivo chimeric antigen receptor (CAR) T cell therapy is limited by cumbersome manufacturing workflows, prohibitive costs and various treatment-related risks. In vivo CAR-T technology directly generates engineered cells within patients, conferring distinct advantages in operational simplicity, biosafety and clinical accessibility. This review systematically evaluates existing delivery platforms and classifies in vivo CAR-T into two core paradigms: persistent engineering and transient reprogramming, each featuring distinct properties tailored to different clinical indications. It further summarizes preclinical advances and clinical data covering hematological malignancies, solid tumors, autoimmune disorders and organ fibrosis, in which numerous investigational candidates have exhibited encouraging efficacy. Ultimately, five translational barriers summarized as the 5S challenges (specificity, stability, safety, suppression and scalability) and their matched optimization tactics are comprehensively discussed. This review provides a clinician-oriented decision matrix that links carriers selection to disease biology, and a 5S optimization framework to guide next-generation vector design. Collectively, these insights establish a translational roadmap for customizing in vivo CAR-T design to specific clinical indications and take a critical step toward realizing the full therapeutic potential of this disruptive modality.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ren, Y., Lin, H., & Wei, J. (2026). In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation. Journal of Controlled Release, 400(Pt A), 115511. https://doi.org/10.1016/j.jconrel.2026.115511
MLA 9
Ren, Yujie, et al. “In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation.” Journal of Controlled Release, vol. 400, no. Pt A, 2026, p. 115511. https://doi.org/10.1016/j.jconrel.2026.115511.
Chicago
Ren, Yujie, Haolong Lin, and Jia Wei. 2026. “In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation.” Journal of Controlled Release 400 (Pt A): 115511. https://doi.org/10.1016/j.jconrel.2026.115511.
Harvard
Ren, Y., Lin, H. and Wei, J. (2026) ‘In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation’, Journal of Controlled Release, 400(Pt A), p. 115511. doi:10.1016/j.jconrel.2026.115511.
IEEE
Y. Ren, H. Lin, and J. Wei, “In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation,” Journal of Controlled Release, vol. 400, no. Pt A, p. 115511, 2026, doi: 10.1016/j.jconrel.2026.115511.
BibTeX
@article{ren2026vivo,
title = {{In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation}},
author = {Ren, Yujie and Lin, Haolong and Wei, Jia},
journal = {Journal of Controlled Release},
year = {2026},
volume = {400},
number = {Pt A},
pages = {115511},
doi = {10.1016/j.jconrel.2026.115511},
url = {https://doi.org/10.1016/j.jconrel.2026.115511}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- chimeric antigen receptor
- hematologic malignancies
- solid tumors
- autoimmune disease
- organ fibrosis
- vector design
- clinical translation
- translational barriers
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Ren, Y., Lin, H., & Wei, J. (2026). In vivo chimeric antigen receptor T cell therapy: From mechanistic innovation to clinical translation. Journal of Controlled Release, 400(Pt A), 115511. https://doi.org/10.1016/j.jconrel.2026.115511
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Controlled Release: sign in and open the PDF from this page.
Who wrote this paper?
Yujie Ren, Haolong Lin, Jia Wei.
What is the DOI of this paper?
10.1016/j.jconrel.2026.115511, permanently at https://doi.org/10.1016/j.jconrel.2026.115511. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.